We are live on ! Find out more
SLNO

Soleno Therapeutics

Delisted

SLNO was delisted on the 15th of May, 2026.

248 hedge funds and large institutions have $3.01B invested in Soleno Therapeutics in 2025 Q4 according to their latest regulatory filings, with 63 funds opening new positions, 102 increasing their positions, 65 reducing their positions, and 49 closing their positions.

New
Increased
Maintained
Reduced
Closed

88% more call options, than puts

Call options by funds: $112M | Put options by funds: $59.8M

57% more repeat investments, than reductions

Existing positions increased: 102 | Existing positions reduced: 65

29% more first-time investments, than exits

New positions opened: 63 | Existing positions closed: 49

3% more funds holding

Funds holding: 240248 (+8)

1.85% less ownership

Funds ownership: 122.73%120.89% (-1.8%)

25% less funds holding in top 10

Funds holding in top 10: 129 (-3)

32% less capital invested

Capital invested by funds: $4.4B → $3.01B (-$1.4B)

Holders
248
Holders Change
+8
Holders Change %
+3.33%
% of All Funds
3%
Holding in Top 10
9
Holding in Top 10 Change
-3
Holding in Top 10 Change %
-25%
% of All Funds
0.11%
New
63
Increased
102
Reduced
65
Closed
49
Calls
$112M
Puts
$59.8M
Net Calls
+$52.5M
Net Calls Change
+$73M
Name Holding Trade Value Shares
Change
Change in
Stake
D.E. Shaw & Co
176
D.E. Shaw & Co
New York
$267K -$110K -1,999 -26%
PCP
177
Perbak Capital Partners
United Kingdom
$267K +$31.6K +577 +11%
EC
178
EntryPoint Capital
New York
$267K +$316K +5,766 New
PCM
179
Prelude Capital Management
New York
$249K -$604K -11,015 -67%
VIA
180
Virtus Investment Advisers
Connecticut
$237K +$203K +3,697 +261%
FCM
181
Farallon Capital Management
California
$232K -$8.11M -148,000 -97%
DAM
182
DLD Asset Management
New York
$232K +$274K +5,000 New
CAU
183
Caxton Associates (UK)
$230K +$272K +4,959 New
Creative Planning
184
Creative Planning
Kansas
$222K -$5.26K -96 -2%
HF
185
HRT Financial
New York
$221K +$262K +4,784 New
MML Investors Services
186
MML Investors Services
Massachusetts
$220K +$261K +4,757 New
SC
187
Shay Capital
New York
$213K +$252K +4,600 New
Public Employees Retirement Association of Colorado
188
Public Employees Retirement Association of Colorado
Colorado
$205K
AIP
189
Ameritas Investment Partners
Nebraska
$175K +$16.5K +301 +9%
FIA
190
FNY Investment Advisers
New York
$162K +$164K +3,000 +600%
Ensign Peak Advisors
191
Ensign Peak Advisors
Utah
$155K -$11.2M -205,162 -98%
AF
192
Avanza Fonder
Sweden
$148K +$17.7K +323 +11%
QT
193
Quantbot Technologies
New York
$144K +$117K +2,132 +216%
A
194
AlphaQuest
New York
$111K +$33.3K +608 +34%
Comerica Bank
195
Comerica Bank
Texas
$108K -$9.02M -164,496 -99%
BG
196
Bollard Group
Massachusetts
$106K
Osaic Holdings
197
Osaic Holdings
Arizona
$88.4K +$21.2K +386 +25%
AB
198
Amalgamated Bank
New York
$68K +$31.9K +581 +66%
KBC Group
199
KBC Group
Belgium
$63K
US Bancorp
200
US Bancorp
Minnesota
$62.2K -$51.2K -934 -41%

SLNO Hedge Fund Activity: Q4 2025 in Review

248 of the 8,256 institutional investors tracked by Wall St. Rank reported a position in Soleno Therapeutics (SLNO) for Q4 2025, worth a combined $3.01B — down 32% from $4.4B a quarter earlier.

Buyers outnumbered sellers: 63 funds opened new SLNO positions and 49 closed out — a net gain of 14 holders — while 102 added to existing stakes and 65 trimmed.

The largest buyer was Janus Henderson Group, adding an estimated $61.5M. The largest seller was Adage Capital Partners, exiting entirely with an estimated $94.7M sold.

  • 248 institutional investors held Soleno Therapeutics (SLNO) as of Q4 2025, up from 240 in Q3 2025.
  • Funds reported $3.01B of Soleno Therapeutics stock for Q4 2025, down 32% quarter-over-quarter.
  • 63 funds opened new Soleno Therapeutics positions in Q4 2025 and 49 closed out, a net change of +14 holders.
  • The largest Soleno Therapeutics buyer in Q4 2025 was Janus Henderson Group, an estimated $61.5M added.
  • The largest Soleno Therapeutics seller in Q4 2025 was Adage Capital Partners, an estimated $94.7M sold.

Based on aggregated 13F filings for Q4 2025.